Agilent and Veeda Lifesciences open joint analytical Centre of Excellence in Bengaluru

Agilent Technologies has announced a strategic collaboration with Veeda Lifesciences to strengthen regulatory‑aligned analytical and bioanalytical workflows supporting biopharma development, as GLP‑1 and other complex therapeutic modalities continue to advance rapidly through global pipelines.

The collaboration brings together Agilent’s expertise in analytical workflow development with Veeda’s established bioanalytical, clinical research and regulatory capabilities, with the objective of enabling high‑quality, inspection‑ready analytical data across early development, clinical, and manufacturing stages.

Together, the two organisations aim to support biopharma companies navigating increasingly complex regulatory and data expectations for next‑generation therapies.

Central to the collaboration is the establishment of a joint Centre of Excellence (CoE) at Veeda’s biopharma facility in Bengaluru. Designed as a scalable analytics and regulatory‑readiness hub, the CoE will focus on the development and validation of end‑to‑end analytical workflows.

The CoE will address the growing analytical demands associated with next‑generation therapies, including GLP‑1 based drugs - where sensitivity, throughput, and data integrity are critical to support regulatory confidence and program progression.

By combining Agilent’s high-performance mass spectrometry with Veeda’s integrated bioanalytical and clinical research infrastructure, the partnership aims to extend services to sponsors across an expanding range of next-generation modalities with consistent, inspection-ready datasets.